Current News

Contact | Print version | PDF version | Send article | RSS feed

Microbix partners with Angiogen for urokinase cancer treatment

06 Nov 2006 - Microbix Biosystems Inc. is partnering with Angiogen LLC to commercialize a novel technology for the treatment of solid cancers by exclusively providing the urokinase needed for Angiogen's patented drug therapy. According to the company, Microbix made a large investment this year in its product pipeline starting with the acquisition of a new production site in Toronto with the capacity to produce commercial quantities of urokinase.
 
"Having this facility and the urokinase technology allowed us to establish an exclusive relationship with Angiogen, the company that has a patented use of urokinase as they pursue indications in the treatment of cancers such as colorectal and prostate," said William J. Gastle, President and CEO of Microbix.
 
Financial activities required to complete Phase 1 and Phase 2 clinical trials are expected to conclude in 2007 after which the companies expect to complete the Phase 1 trial in 2008.